The DOI matches its Crossref record; 208 of the 208 references it cites were found in a registry or an index.
A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association
Open accessAbstract
A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led to the conceptualization of cardiovascular-kidney-metabolic syndrome. The confluence of metabolic risk factors and chronic kidney disease within cardiovascular-kidney-metabolic syndrome is strongly linked to risk for adverse cardiovascular and kidney outcomes. In addition, there are unique management considerations for individuals with established cardiovascular disease and coexisting metabolic risk factors, chronic kidney disease, or both. An extensive body of literature supports our scientific understanding of, and approach to, prevention and management for individuals with cardiovascular-kidney-metabolic syndrome. However, there are critical gaps in knowledge related to cardiovascular-kidney-metabolic syndrome in terms of mechanisms of disease development, heterogeneity within clinical phenotypes, interplay between social determinants of health and biological risk factors, and accurate assessments of disease incidence in the context of competing risks. There are also key limitations in the data supporting the clinical care for cardiovascular-kidney-metabolic syndrome, particularly in terms of early-life prevention, screening for risk factors, interdisciplinary care models, optimal strategies for supporting lifestyle modification and weight loss, targeting of emerging cardioprotective and kidney-protective therapies, management of patients with both cardiovascular disease and chronic kidney disease, and the impact of systematically assessing and addressing social determinants of health. This scientific statement uses a crosswalk of major guidelines, in addition to a review of the scientific literature, to summarize the evidence and fundamental gaps related to the science, screening, prevention, and management of cardiovascular-kidney-metabolic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Assessments for prediabetes or diabetes with fasting blood glucose, HbA1c, or oral glucose tolerance tests are critical because of the strong association of hyperglycemia with cardiovascular and kidney disease.39,40”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Successful interventions included frequent feedback and support, which have been shown to positively impact program adherence.24”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both classes of agents reduce major adverse cardiovascular events (MACE) and CVD mortality across multiple clinical trials,39,40 with SGLT2i having a particular impact on HF hospitalizations and GLP-1–based therapy having a more substantial impact than SGLT2i on incident ASCVD events.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both classes of agents reduce major adverse cardiovascular events (MACE) and CVD mortality across multiple clinical trials,39,40 with SGLT2i having a particular impact on HF hospitalizations and GLP-1–based therapy having a more substantial impact than SGLT2i on incident ASCVD events.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Incidentally identified moderate-to-severe coronary calcifications on a nongated chest computed tomography scan typically correlates with CAC ≥100, carries similar prognostic value, and can also identify patients with CKM syndrome most likely to benefit from preventive therapies.21–24”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [24]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In adults across the CKM stages, intensive lifestyle interventions and intensive risk factor control with coordinated care and pharmacotherapies have robust evidence of improving CKM health.22–24”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1–based therapy often causes significant weight loss and improvements in CKM risk profiles and MASLD, while SGLT2i has a marked impact on CKD.19–30”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MBS causes substantial weight loss (up to 30% to 35% body weight) and improvements in multiple CKM risk factors.23–25”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both SGLT2i and GLP-1–based therapy improve kidney outcomes,49–51 with GLP-1–based therapy additionally promoting significant weight reduction and glycemic control (especially semaglutide and tirzepatide)19–25 and reducing liver fibrosis in MASH”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The risk-benefit and appropriate strategies for treating obesity in patients with HFrEF remain undefined.24”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“RASi, with ARNI having superior HF benefits over ACEi/ARB; and 2) SGLT2i.13,21–25”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among these 4 medication classes (6 classes if the patient also self-identifies as Black race), 2 are kidney-protective; namely, 1) RASi, with ARNI having superior HF benefits over ACEi/ARB; and 2) SGLT2i.13,21–25”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MBS is associated with a lower risk of incident major adverse liver outcomes and MACE in large cohort studies.6,24,25”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In patients with BMI ≥30 kg/m2, pooled DOAC use was linked to a 20% reduction in stroke/systemic embolism/MI/all-cause mortality and a 44% reduction in major bleeding versus VKA, with similar VTE prevention.24”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The early postpartum period representing the 12 weeks following delivery, sometimes referred to as the fourth trimester, is a critical window to optimize women's CKM health, particularly for women with APOs.40”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The largest HbA1c reductions are achieved by treatment plans that include GLP-1–based treatments, particularly semaglutide and tirzepatide, in addition to insulin.24,25”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOs are also associated with higher subsequent risk for developing CKM risk factors (hypertension, diabetes, dyslipidemia) and CVD (including HF, coronary heart disease, PAD, and vascular dementia).12,23–27”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The AHA and ACOG recommend frequent CVD risk factor screening and lifestyle counseling among postpartum women who experience APOs.40,41”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Both classes of agents reduce major adverse cardiovascular events (MACE) and CVD mortality across multiple clinical trials,39,40 with SGLT2i having a particular impact on HF hospitalizations and GLP-1–based therapy having a more substantial impact than SGLT2i on incident ASCVD events.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“SGLT2i appear to primarily reduce incident and worsening HF.17,37–44”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“As such, the current study supports IPE as a potential therapeutic strategy for CKM patients beyond traditional standard of care measures as outlined in the recent AHA Scientific Statement [3]”
From Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM (2026) · cites this paper as [3]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Another small RCT showed that a social work–led care coordination intervention reduced 30-day readmission rates by 22% among older inpatients with high risk of readmission.24”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A systematic review of registry data reported several strategies for successful weight loss maintenance, including regular breakfast intake and having healthy food at home.40”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A recently published modeling study suggested that GLP-1-based therapies, at an annual cost of $19 881, would not be cost-effective compared with RYGB surgery.24”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Lactation also reduces pancreatic oxidative stress and risks for T2D in women with GDM and should be discussed with them before, during, and after pregnancy.22–24”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This benefit was consistent with or without background SGLT2i40 or GLP-1 RA use.41”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“numerous observational studies support a positive, linear association of glycemia with HF incidence and events.23–25”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In adults with CKM syndrome stage 4 syndrome with CKD and symptomatic HFpEF, the cost-effectiveness of adding a SGLT2i prior to GDMT at 2025 US prices is indeterminate.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, these analyses pooled individuals without, and with, CKD and did not directly incorporate the benefit of SGLT2i therapy on kidney outcomes.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Metabolic and bariatric surgery causes remission of MASLD, even in advanced stages.6,24,25”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“One analysis based on the results of the EMPEROR-PRESERVED trial found that empagliflozin therapy, at an annual cost of $3920, would have an incremental cost-effectiveness ratio $437 400 per QALY gained.40”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In 2 high-quality simulation model–based cost-effectiveness analyses that evaluated the economic value of adding SGLT2i therapy to prior GDMT in adults with symptomatic HFpEF using a US health care sector perspective and a lifetime analytic horizon, addition of SGLT2i therapy to GDMT was projected to be not cost-effective, but the incremental cost-effectiveness ratio was sensitive to the effect on”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Taken together, these analyses suggest that SGLT2i therapy is not cost-effective at current drug prices (incremental cost-effectiveness ratio ≥$120 000 per QALY gained).”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The effects of RASi, SGLT2i, and nsMRA on albuminuria are evident within weeks of initiation,40–42”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“95,134”
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Self-citationChronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 10,550
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“165,205 In individuals with diabetes and ASCVD, the approach to prioritizing selection of SGLT2 inhibitors versus GLP-1RAs is unclear because these therapies have not been directly compared in clinical trials.”
Background2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Self-citationThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“Newer obesity pharmaco-therapies, particularly high-dose GLP-1RA and GLP1/ GIP-RA agents, induce marked weight loss and improve metabolic risk factors, 199,200 but the optimal targeting of these agents as adjuncts to lifestyle modification in the broad population with obesity is unclear.”
BackgroundObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Self-citationFlynn, J. T., Kaelber, D. C., Baker-Smith, C. M., Blowey, D., Carroll, A. E., Daniels, S. R., de Ferranti, S. D., Dionne, J. M., Falkner, B., Flinn, S. K., et al. (2017) · Pediatrics · doi:10.1542/peds.2017-1904 · Cited by 3,651
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465 · cited 1×
“139”
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Lloyd-Jones, D. M., Allen, N. B., Anderson, C. A. M., Black, T., Brewer, L. C., Foraker, R. E., Grandner, M. A., Lavretsky, H., Perak, A. M., Sharma, G., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001078 · Cited by 2,785
Empagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000665 · Cited by 2,744
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001184 · Cited by 2,208
Self-citationMetabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus
Wilson, P. W. F., D’Agostino, R. B., Parise, H., SULLIVAN, L. M., & Meigs, J. B. (2005) · Circulation · doi:10.1161/circulationaha.105.539528 · Cited by 2,050
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Ross, R., Neeland, I. J., Yamashita, S., Shai, I., Seidell, J., Magni, P., Santos, R. D., Arsenault, B., Cuevas, A., Hu, F. B., et al. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0310-7 · Cited by 1,966
Self-citationWing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Global trends in diabetes complications: a review of current evidence
Harding, J. L., Pavkov, M. E., Magliano, D. J., Shaw, J. E., & Gregg, E. W. (2018) · Diabetologia · doi:10.1007/s00125-018-4711-2 · Cited by 1,765
Changes in diabetes-related complications in the United States, 1990-2010
Gregg, E. W., Li, Y., Wang, J., Rios Burrows, N., Ali, M. K., Rolka, D., Williams, D. E., & Geiss, L. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310799 · Cited by 1,749
Social determinants of health and diabetes: A scientific review
Hill-Briggs, F., Adler, N. E., Berkowitz, S. A., Chin, M. H., Gary-Webb, T. L., Navas-Acien, A., Thornton, P. L., & Haire-Joshu, D. (2021) · Diabetes Care · doi:10.2337/dci20-0053 · Cited by 1,732
Childhood Adiposity, Adult Adiposity, and Cardiovascular Risk Factors
Juonala, M., Magnussen, C. G., Berenson, G. S., Venn, A., Burns, T. L., Sabin, M. A., Srinivasan, S. R., Daniels, S. R., Davis, P. H., Chen, W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010112 · Cited by 1,665
Bariatric Surgery and Long-term Cardiovascular Events
Sjöström, L., Peltonen, M., Jacobson, P., Sjöström, C. D., Karason, K., Wedel, H., Ahlin, S., Anveden, Å., Bengtsson, C., Bergmark, G., et al. (2012) · JAMA · doi:10.1001/jama.2011.1914 · Cited by 1,656
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement
Neeland, I. J., Ross, R., Després, J.-P., Matsuzawa, Y., Yamashita, S., Shai, I., Seidell, J., Magni, P., Santos, R. D., Arsenault, B., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30084-1 · Cited by 1,603
Self-citationSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 1×
“153,161 SGLT2 inhibitors additionally reduce the risk for HF hospitalization and worsening kidney function in patients with ASCVD, whereas GLP-1RAs have more potent effects than SGLT2 inhibitors on weight and HbA1c.”
BackgroundRangaswami, J., Bhalla, V., Blair, J. E., Chang, T. I., Costa, S. P., Lentine, K. L., Lerma, E. V., Mezue, K. N., Molitch, M. E., Müllens, W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000664 · Cited by 1,535
Self-citationReduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
The Look AHEAD Research Group (2007) · Diabetes Care · doi:10.2337/dc07-0048 · Cited by 1,522
Body Fat Distribution and Risk of Cardiovascular Disease: An Update
Després, J.-P. (2012) · Circulation · doi:10.1161/circulationaha.111.067264 · Cited by 1,481 · cited 1×
“46 In addition, there are significant racial and ethnic differences in the propensity for metabolic risk factors at a given weight.”
BackgroundSelf-citationInterventions for preventing obesity in children
Waters, E., de Silva-Sanigorski, A., Burford, B. J., Brown, T., Campbell, K. J., Gao, Y., Armstrong, R., Prosser, L., & Summerbell, C. D. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001871.pub3 · Cited by 1,455
Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.11.003 · Cited by 1,452
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444 · cited 1×
“In addition, the discontinuation of these agents is associated with weight regain, 201 and strategies for successful weight maintenance with reductions or discontinuation of newer obesity pharmacotherapies are undefined.”
BackgroundHampl, S. E., Hassink, S. G., Skinner, A. C., Armstrong, S. C., Barlow, S. E., Bolling, C. F., Avila Edwards, K. C., Eneli, I., Hamre, R., Joseph, M. M., et al. (2023) · Pediatrics · doi:10.1542/peds.2022-060640 · Cited by 1,389 · cited 2×
“91 Pediatric obesity and pediatric CKD precede the development of other CKM risk factors.”
BackgroundKDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Self-citationAgarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab777 · Cited by 1,317 · cited 2×
“149 In the SHARP trial (Study of Heart and Renal Protection), among patients with CKD (almost half of whom were on dialysis) with no known history of ASCVD, patients randomized to simvastatin plus ezeti-mibe compared with placebo had a significant reduction in first major atherosclerotic events.”
BackgroundKidney disease and increased mortality risk in type 2 diabetes
Afkarian, M., Sachs, M. C., Kestenbaum, B., Hirsch, I. B., Tuttle, K. R., Himmelfarb, J., & de Boer, I. H. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012070718 · Cited by 1,298
Self-citationMcGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Chapter 1: Definition and classification of CKD
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.64 · Cited by 1,148
Obesity in children and adolescents: epidemiology, causes, assessment, and management
Jebeile, H., Kelly, A. S., O'Malley, G., & Baur, L. A. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00047-x · Cited by 1,099
van der Velde, M., Matsushita, K., Coresh, J., Astor, B. C., Woodward, M., Levey, A. S., de Jong, P. E., & Gansevoort, R. T. (2011) · Kidney International · doi:10.1038/ki.2010.536 · Cited by 1,082
Self-citationAmsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000134 · Cited by 1,059
In-Center Hemodialysis Six Times per Week versus Three Times per Week
The FHN Trial Group (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001593 · Cited by 1,022
Baigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02074-8 · Cited by 1,020
Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01429-5 · Cited by 996
Self-citationStrict Blood-Pressure Control and Progression of Renal Failure in Children
The ESCAPE Trial Group (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902066 · Cited by 954
Peripheral arterial disease in people with diabetes
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3333 · Cited by 953
Social Determinants of Cardiovascular Disease
Powell‐Wiley, T. M., Baumer, Y., Baah, F. O., Baez, A. S., Farmer, N., Mahlobo, C. T., Pita, M. A., Potharaju, K. A., Tamura, K., & Wallen, G. R. (2022) · Circulation Research · doi:10.1161/circresaha.121.319811 · Cited by 934
Self-citationKitzman, D. W., Brubaker, P., Morgan, T., Haykowsky, M., Hundley, G., Kraus, W. E., Eggebeen, J., & Nicklas, B. J. (2016) · JAMA · doi:10.1001/jama.2015.17346 · Cited by 921
de Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022) · Diabetes Care · doi:10.2337/dci22-0027 · Cited by 919 · cited 3×
“58,69,80 The Kidney Disease Improving Global Outcomes CKD staging system combines eGFR and albuminuria to provide a broad risk estimate for CKD progression, CVD events, and overall mortality.”
BackgroundSelf-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
Screening for Obesity in Children and Adolescents
US Preventive Services Task Force, Grossman, D. C., Bibbins-Domingo, K. B., Curry, S. J., Barry, M. J., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., Krist, A. H., et al. (2017) · JAMA · doi:10.1001/jama.2017.6803 · Cited by 837
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210645 · Cited by 749 · cited 1×
“206 It has been speculated that this may be linked to greater reduction of apolipoprotein B concentrations with icosa-pent ethyl, 207 but more research on this topic is needed.”
BackgroundSelf-citationHeart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Self-citationMolecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 724
Self-citationJanssen, I., Heymsfield, S. B., Allison, D. B., Kotler, D. P., & Ross, R. (2002) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/75.4.683 · Cited by 719
Kavey, R.-E. W., Allada, V., Daniels, S. R., Hayman, L. L., McCrindle, B. W., Newburger, J. W., Parekh, R. S., & Steinberger, J. (2006) · Circulation · doi:10.1161/circulationaha.106.179568 · Cited by 707
The Global Epidemiology of Diabetes and Kidney Disease
Koye, D. N., Magliano, D. J., Nelson, R. G., & Pavkov, M. E. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.10.011 · Cited by 686
Budoff, M. J., Young, R., Burke, G., Jeffrey Carr, J., Detrano, R. C., Folsom, A. R., Kronmal, R., Lima, J. A. C., Liu, K. J., McClelland, R. L., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy217 · Cited by 684
Ledwidge, M., Gallagher, J., Conlon, C., Tallon, E., O’Connell, E., Dawkins, I., Watson, C., O’Hanlon, R., Bermingham, M., Patle, A., et al. (2013) · JAMA · doi:10.1001/jama.2013.7588 · Cited by 664
Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Self-citationChildhood Cardiovascular Risk Factors and Adult Cardiovascular Events
Jacobs, D. R., Woo, J. G., Sinaiko, A. R., Daniels, S. R., Ikonen, J., Juonala, M., Kartiosuo, N., Lehtimäki, T. J., Magnussen, C. G., Viikari, J. S. A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109191 · Cited by 652
Epigenetics and epigenomics in diabetic kidney disease and metabolic memory
Kato, M. V., & Natarajan, R. D. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0135-6 · Cited by 615
Bethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30412-6 · Cited by 599
Anti-inflammatory therapies for cardiovascular disease
Ridker, P. M., & Lüscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu203 · Cited by 568
Lloyd-Jones, D. M., Braun, L. T., Ndumele, C. E., Smith, S. C., Sperling, L. S., Virani, S. S., & Blumenthal, R. S. (2019) · Circulation · doi:10.1161/cir.0000000000000638 · Cited by 554 · cited 1×
“101 Although carotid intima-media thickness is also associated with ASCVD, the magnitude of association is diminished compared with CAC, and the relationship of carotid intima-media thickness to treat-ment remains controversial.”
BackgroundSelf-citationAroda, V. R., Christophi, C. A., Edelstein, S. L., Zhang, P., Herman, W. H., Barrett-Connor, E., Delahanty, L. M., Montez, M. G., Ackermann, R. T., Zhuo, X., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3761 · Cited by 467
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465 · cited 2×
“62,63,69,76,77 Obesity confers greater risk with longer severity and duration, supporting the concept of addressing excess weight at early points in the life course.”
BackgroundSelf-citationRodbard, H. W., Rosenstock, J., Canani, L. H., Deerochanawong, C., Gumprecht, J., Lindberg, S. Ø., Lingvay, I., Søndergaard, A. L., Treppendahl, M. B., Montanya, E., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0883 · Cited by 463
Final Report of a Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa1901281 · Cited by 454
Pop‐Busui, R., Januzzi, J. L., Bruemmer, D., Butalia, S., Green, J. B., Horton, W. B., Knight, C. M., Levi, M., Rasouli, N., & Richardson, C. R. (2022) · Diabetes Care · doi:10.2337/dci22-0014 · Cited by 442
Metabolically Healthy Obesity, Transition to Metabolic Syndrome, and Cardiovascular Risk
Mongraw‐Chaffin, M., Foster, M. C., Anderson, C. A. M., Burke, G. L., Haq, N., Kalyani, R. R., Ouyang, P., Sibley, C. T., Tracy, R. P., Woodward, M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.055 · Cited by 435
Müllens, W., Damman, K., Testani, J. M., Martens, P., Mueller, C. E., Lassus, J. P. E., Tang, W. H. W., Skouri, H. N., Verbrugge, F. H., Orso, F., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1697 · Cited by 431
Giugliano, R. P., Cannon, C. P., Blazing, M. A., Nicolau, J. C., Corbalán, R., Špinar, J., Park, J.-G., White, J. A., Bohula, E. A., & Braunwald, E. (2018) · Circulation · doi:10.1161/circulationaha.117.030950 · Cited by 427
Cardiovascular Disease in Children with Chronic Kidney Disease
Mitsnefes, M. M. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011111115 · Cited by 426
Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy
Shahzad, K., Bock, F. M., Dong, W., Wang, H., Kopf, S., Kohli, S., Al‐Dabet, M. M., Ranjan, S., Wolter, J., Wacker, C., et al. (2014) · Kidney International · doi:10.1038/ki.2014.271 · Cited by 423
Linz, D., McEvoy, R. D., Cowie, M. R., Somers, V. K., Nattel, S., Lévy, P., Kalman, J. M., & Sanders, P. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.0095 · Cited by 411
Huelsmann, M., Neuhold, S., Resl, M., Strunk, G., Brath, H., Francesconi, C., Adlbrecht, C., Prager, R., Luger, A., Pacher, R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.069 · Cited by 385
Chen, J., Budoff, M. J., Reilly, M. P., Yang, W. P., Rosas, S. E., Rahman, M., Zhang, X., Roy, J. A., Lustigova, E., Nessel, L. C., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.0363 · Cited by 367
Self-citationIntroduction and Methodology: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Cusi, K., Das, S. R., Gibbons, C. H., et al. (2023) · Diabetes Care · doi:10.2337/dc23-sint · Cited by 366
Self-citationKreuter, M. W., Thompson, T., McQueen, A., & Garg, R. (2020) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-090419-102204 · Cited by 352
Microalbuminuria and Cardiovascular Disease
Weir, M. R. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03190906 · Cited by 342
Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring
Mitchell, J. D., Fergestrom, N. M., Gage, B. F., Paisley, R., Moon, P. S., Novak, E. L., Cheezum, M. K., Shaw, L. J., & Villines, T. C. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.051 · Cited by 323
Konstam, M. A., Kronenberg, M. W., Rousseau, M. F., Udelson, J. E., Melin, J., Stewart, D., Dolan, N., Edens, T. R., Ahn, S., & Kinan, D. (1993) · Circulation · doi:10.1161/01.cir.88.5.2277 · Cited by 316
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D. M., Johnson, E. L., et al. (2022) · Diabetes Care · doi:10.2337/dc23-s011 · Cited by 310
Pichler, R. H., Afkarian, M., Dieter, B. P., & Tuttle, K. R. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00314.2016 · Cited by 308
Self-citationJhund, P. S., Kondo, T., Butt, J. H., Docherty, K. F., Claggett, B. L., Desai, A. S., Vaduganathan, M., Gasparyan, S. B., Bengtsson, O., Lindholm, D. P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01971-4 · Cited by 307
Self-citationNeuen, B. L., Oshima, M., Agarwal, R., Arnott, C. G., Cherney, D. Z. I., Edwards, R., Langkilde, A. M., Mahaffey, K. W., McGuire, D. K., Neal, B., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.057736 · Cited by 306
Gepner, A. D., Young, R. L., Delaney, J. A., Tattersall, M. C., Blaha, M. J., Post, W. S., Gottesman, R. F., Kronmal, R. A., Budoff, M. J., Burke, G. L., et al. (2015) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.114.002262 · Cited by 289
Vantrimpont, P., Rouleau, J. L., Wun, C.-C., Ciampi, A., Klein, M., Sussex, B., Arnold, J. M. O., Moyé, L., & Pfeffer, M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00489-5 · Cited by 274
Advances in Revascularization for Peripheral Artery Disease: Revascularization in PAD
Beckman, J. A., Schneider, P. A., & Conte, M. S. (2021) · Circulation Research · doi:10.1161/circresaha.121.318261 · Cited by 262
Hemmingsson, E. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0310-2 · Cited by 261
Hall, M. E., Cohen, J. B., Ard, J. D., Egan, B. M., Hall, J. E., Lavie, C. J., Ma, J., Ndumele, C. E., Schauer, P. R., & Shimbo, D. (2021) · Hypertension · doi:10.1161/hyp.0000000000000202 · Cited by 259
Self-citationWong, R. J., & Singal, A. K. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.20294 · Cited by 254
Screening for Hypertension in Adults
US Preventive Services Task Force, Krist, A. H., Davidson, K. W., Mangione, C. M., Cabana, M. D., Caughey, A. B., Davis, E. M., Donahue, K. E., Doubeni, C. A., Kubik, M., et al. (2021) · JAMA · doi:10.1001/jama.2021.4987 · Cited by 252
Targeting innate immunity-driven inflammation in CKD and cardiovascular disease
Speer, T., Dimmeler, S., Schunk, S. J., Fliser, D., & Ridker, P. M. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00621-9 · Cited by 251
Ryan, D. H., Lingvay, I., Colhoun, H. M., Deanfield, J., Emerson, S. S., Kahn, S. E., Kushner, R. F., Marso, S., Plutzky, J., Brown-Frandsen, K., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.07.008 · Cited by 249 · cited 1×
“162 Studies are also evaluating the impact of GLP-1RAs on symptoms, physical limitations, and exercise function in HFpEF.”
BackgroundRossing, P., Baeres, F. M. M., Bakris, G., Bosch-Traberg, H., Gislum, M., Gough, S. C. L., Idorn, T., Lawson, J., Mahaffey, K. W., Mann, J. F. E., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad009 · Cited by 242
Self-citationLong-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON
Wong, M. G., Perkovic, V., Chalmers, J., Woodward, M., Li, Q., Cooper, M. E., Hamet, P., Harrap, S., Heller, S., MacMahon, S., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2322 · Cited by 240 · cited 1×
“20 Past hyperglycemia leads to long-lasting advanced glycation end products and epigenetic modifications, as well as subsequent upregulation of proinflammatory and profibrotic genes.”
BackgroundBeldhuis, I. E., Lam, C. S. P., Testani, J. M., Voors, A. A., Spall, H. G. C. V., ter Maaten, J. M., & Damman, K. (2022) · Circulation · doi:10.1161/circulationaha.121.052792 · Cited by 239
Rangaswami, J., Mathew, R. O., Parasuraman, R. K., Tantisattamo, E., Lubetzky, M., Rao, S., Yaqub, M. S., Birdwell, K. A., Bennett, W. M., Dalal, P., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz053 · Cited by 223
Self-citationSundström, J., Bruze, G., Ottosson, J., Marcus, C., Näslund, I., & Neovius, M. (2017) · Circulation · doi:10.1161/circulationaha.116.025629 · Cited by 220
Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes
Januzzi, J. L., Butler, J., Jarolı́m, P., Sattar, N. A., Vijapurkar, U., Desai, M. G., & Davies, M. J. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.06.016 · Cited by 215
Doumouras, A. G., Wong, J. A., Paterson, J. M., Lee, Y., Sivapathasundaram, B., Tarride, J.-E., Thabane, L., Hong, D., Yusuf, S., & Anvari, M. (2021) · Circulation · doi:10.1161/circulationaha.120.052386 · Cited by 209
Packham, D. K., Alves, T. P., Dwyer, J. P., Atkins, R., de Zeeuw, D., Cooper, M., Shahinfar, S., Lewis, J. B., & Lambers Heerspink, H. J. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.09.017 · Cited by 205
Cainzos-Achirica, M., Miedema, M. D., McEvoy, J. W., Al Rifai, M., Greenland, P., Dardari, Z., Budoff, M., Blumenthal, R. S., Yeboah, J., Duprez, D. A., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.045010 · Cited by 201
Lloyd-Jones, D. M., Liu, K., Colangelo, L. A., Yan, L. L., Klein, L., Loria, C. M., Lewis, C. E., & Savage, P. (2007) · Circulation · doi:10.1161/circulationaha.106.648642 · Cited by 194
Rangaswami, J., Bhalla, V., de Boer, I. H., Staruschenko, A., Sharp, J. A., Singh, R. R., Lo, K. B., Tuttle, K., Vaduganathan, M., Ventura, H., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000920 · Cited by 192
Self-citationSchuster, N. A., Hoogendijk, E. O., Kok, A. A. L., Twisk, J. W. R., & Heymans, M. W. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.03.004 · Cited by 191
Yan, Q., Chen, Z., Wang, Y., Campbell, J. A., Xue, Q., Williams, M. Y., Weinhardt, L. S., & Egede, L. E. (2022) · Health Equity · doi:10.1089/heq.2022.0010 · Cited by 188
Adipose Tissue Inflammation and Cardiovascular Disease: An Update
Rana, M. N., & Neeland, I. J. (2022) · Current Diabetes Reports · doi:10.1007/s11892-021-01446-9 · Cited by 177
Self-citationScreening for Lipid Disorders in Children and Adolescents
US Preventive Services Task Force, Bibbins-Domingo, K. B., Grossman, D. C., Curry, S. J., Davidson, K. W., Epling, J. W., García, F., Gillman, M. W., Kemper, A. R., Krist, A. H., et al. (2016) · JAMA · doi:10.1001/jama.2016.9852 · Cited by 174
Wright, A. K., Carr, M., Kontopantelis, E., Leelarathna, L., Thabit, H., Emsley, R., Buchan, I. E., Mamas, M. A., van Staa, T. P., Sattar, N. A., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1113 · Cited by 172
Zhu, Y., Sidell, M. A., Arterburn, D. E., Daley, M. F., DESAI, J. R., Fitzpatrick, S. L., Horberg, M. A., Koebnick, C., McCormick, E. V., Oshiro, C. E. S., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0532 · Cited by 170
Covic, A. C., Vervloet, M. G., Massy, Z. A., Ureña, P., Goldsmith, D. J. A., Brandenburg, V. M., Mazzaferro, S., Evenepoel, P., Bover, J., Apetrii, M., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30310-8 · Cited by 164
AMDUR, R. L., Feldman, H. I., Dominic, E. A., Anderson, A. H., Beddhu, S., Rahman, M., Wolf, M. S., Reilly, M. P., OJO, A. O., Townsend, R. R., et al. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.09.012 · Cited by 164
Rossing, P. R., Filippatos, G. S., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Chan, J. C. N., Kooy, A., McCafferty, K., Schernthaner, G., et al. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.10.008 · Cited by 159
Perak, A. M., Ning, H., Khan, S. S., Bundy, J. D., Allen, N. B., Lewis, C. E., Jacobs, D. R., Horn, L. V., & Lloyd‐Jones, D. M. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.10.002 · Cited by 156
Self-citationScreening for Chronic Kidney Disease: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-8-201210160-00533 · Cited by 155
Berg, D. D., Wiviott, S. D., Scirica, B. M., Gurmu, Y., Mosenzon, O., Murphy, S. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042685 · Cited by 154
Transforming Growth Factor-Beta1 in Diabetic Kidney Disease
Zhao, L., Zou, Y., & Liu, F. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00187 · Cited by 153
Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes
Pandey, A., Vaduganathan, M., Patel, K. V., Ayers, C., Ballantyne, C. M., Kosiborod, M. N., Carnethon, M., DeFilippi, C., McGuire, D. K., Khan, S. S., et al. (2021) · JACC: Heart Failure · doi:10.1016/j.jchf.2020.10.013 · Cited by 144
Self-citationPage, K. A., LUO, S. H., Wang, X., Chow, T., Alves, J. M., Buchanan, T. A., & Xiang, A. H. (2019) · Diabetes Care · doi:10.2337/dc18-2581 · Cited by 142
Khan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045888 · Cited by 139
Self-citationAdamson, C., Docherty, K. F., Heerspink, H. J. L., de Boer, R. A., Damman, K., Inzucchi, S. E., Køber, L., Kosiborod, M., Martínez, F. A., Petrie, M. C., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.058910 · Cited by 139
Self-citationDynamic Cardiovascular Risk Assessment in Elderly People
deFilippi, C. R., Christenson, R. H., Gottdiener, J. S., Kop, W. J., & Seliger, S. L. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.069 · Cited by 138
Hildebrandt, P. R., Collinson, P. O., Doughty, R. N., Fuat, A., Gaze, D. C., Gustafsson, F., Januzzi, J. L., Rosenberg, J. T., Senior, R., & Richards, M. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq163 · Cited by 134
Rosenzweig, J. L., Bakris, G. L., Berglund, L., Hivert, M., Horton, E. S., Kalyani, R. R., Murad, M. H., & Vergès, B. L. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01338 · Cited by 133
Sattar, N. A., McMurray, J. J. V., Borén, J., Rawshani, A., Ömerovic, E., Berg, N., Halminen, J., Skoglund, K., Eliasson, B., Gerstein, H. C., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063374 · Cited by 119
Rosuvastatin in Diabetic Hemodialysis Patients
Holdaas, H., Holme, I., Schmieder, R. E., Jardine, A. G., Zannad, F. M., Norby, G. E., & Fellström, B. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010090987 · Cited by 118
Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy
Ridker, P. M., Tuttle, K. R., Perkovic, V., Libby, P., & MacFadyen, J. G. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac444 · Cited by 117
Self-citationLiu, Z., Gao, P., Gao, A.-Y., Lin, Y., Feng, X.-X., Zhang, F., Xu, L.-Q., Niu, W.-Y., Fang, H., Zhou, S., et al. (2022) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2021.4375 · Cited by 116
KDOQI US Commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD
Sarnak, M. J., Bloom, R. D., Muntner, P., Rahman, M., Saland, J. M., Wilson, P. W. F., & Fried, L. P. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.10.005 · Cited by 114
Gudzune, K. A., Bennett, W. L., Cooper, L. A., & Bleich, S. N. (2014) · Preventive Medicine · doi:10.1016/j.ypmed.2014.02.001 · Cited by 114
ALLHAT Findings Revisited in the Context of Subsequent Analyses, Other Trials, and Meta-analyses
Wright, J. T. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.60 · Cited by 112
Self-citationBody Fat and Body-Mass Index among a Multiethnic Sample of College-Age Men and Women
Carpenter, C. L., Yan, E., Chen, S., Hong, K. M., Aréchiga, A. E., Kim, W. S., Deng, M., Li, Z., & Heber, D. (2013) · Journal of Obesity · doi:10.1155/2013/790654 · Cited by 111
Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes
Pagidipati, N. J., Nelson, A. J., Kaltenbach, L. A., Leyva, M., McGuire, D. K., Pop‐Busui, R., Cavender, M. A., Aroda, V. R., MAGWIRE, M. L., Richardson, C. R., et al. (2023) · JAMA · doi:10.1001/jama.2023.2854 · Cited by 108
Systematic integrated analysis of genetic and epigenetic variation in diabetic kidney disease
Sheng, X., Qiu, C., Liu, H., Gluck, C. A., Hsu, J. Y., He, J., Hsu, C., Sha, D., Weir, M. R., Isakova, T., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005905117 · Cited by 106
Wang, K., Hu, J., Luo, T., Wang, Y., Yang, S., 青华, Cheng, Q., & Li, Q. (2018) · Kidney & Blood Pressure Research · doi:10.1159/000489913 · Cited by 105
Integrating Social Care Into the Delivery of Health Care
Bibbins-Domingo, K. B. (2019) · JAMA · doi:10.1001/jama.2019.15603 · Cited by 103
Reported Cases of End-Stage Kidney Disease — United States, 2000–2019
Burrows, N. R., Koyama, A. K., & Pavkov, M. E. (2022) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7111a3 · Cited by 102
Bansal, N., Artinian, N. T., Bakris, G. L., Chang, T. I., Cohen, J. B., Flythe, J. E., Lea, J. P., Vongpatanasin, W., & Chertow, G. M. (2023) · Hypertension · doi:10.1161/hyp.0000000000000230 · Cited by 101
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Christensen, L., Davies, M., Hovingh, K. G., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · JACC: Heart Failure · doi:10.1016/j.jchf.2023.05.010 · Cited by 97 · cited 2×
“168 If these trials have positive results, patients with obesity and prevalent CVD might be prioritized these agents.”
BackgroundSelf-citationPatel, J., Pallazola, V. A., Dudum, R., Greenland, P., McEvoy, J. W., Blumenthal, R. S., Virani, S. S., Miedema, M. D., Shea, S., Yeboah, J., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2321 · Cited by 88
Self-citationScreening for High Blood Pressure in Children and Adolescents
US Preventive Services Task Force, Krist, A. H., Davidson, K. W., Mangione, C. M., Barry, M. J., Cabana, M. D., Caughey, A. B., Donahue, K. E., Doubeni, C. A., Epling, J. W., et al. (2020) · JAMA · doi:10.1001/jama.2020.20122 · Cited by 87
Management of Obesity in Cardiovascular Practice
Després, J.-P., Carpentier, A. C., Tchernof, A., Neeland, I. J., & Poirier, P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.035 · Cited by 87
Self-citationCardiovascular Outcomes in Patients With Diabetes and Kidney Disease
Morales, J., & Handelsman, Y. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.052 · Cited by 86
Leiter, L. A., Betteridge, D. J., Farnier, M., Guyton, J. R., Lin, J., Shah, A., Johnson‐Levonas, A. O., & Brudi, P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01383.x · Cited by 84
Epigenetics of Early Cardiometabolic Disease: Mechanisms and Precision Medicine
Baccarelli, A., & Ordovás, J. M. (2023) · Circulation Research · doi:10.1161/circresaha.123.322135 · Cited by 83
Cardiovascular Disease in CKD in Children: Update on Risk Factors, Risk Assessment, and Management
Wilson, A. C., & Mitsnefes, M. M. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.04.027 · Cited by 82
Spannella, F., Giulietti, F., Filipponi, A., & Sarzani, R. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13002 · Cited by 82
Cardio-Renal-Metabolic Care Models
Rangaswami, J., Tuttle, K. R., & Vaduganathan, M. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.007264 · Cited by 80
Self-citationSafian, R. D. (2021) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2021.03.003 · Cited by 75
Regional Fat Distribution and Blood Pressure Level and Variability
Yano, Y., Vongpatanasin, W., Ayers, C. R., Turer, A. T., Chandra, A., Carnethon, M. R., Greenland, P., de Lemos, J. A., & Neeland, I. J. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07876 · Cited by 67
Self-citationScreening for Prediabetes and Type 2 Diabetes in Children and Adolescents
US Preventive Services Task Force, Mangione, C. M., Barry, M. J., Nicholson, W. K., Cabana, M. D., Chelmow, D. P., Coker, T. R., Davidson, K. W., Davis, E. M., Donahue, K. E., et al. (2022) · JAMA · doi:10.1001/jama.2022.14543 · Cited by 67
Sarnak, M. J., Auguste, B. L., Brown, E. A., Chang, A. R., Chertow, G. M., Hannan, M. F., Herzog, C. A., Nadeau‐Fredette, A., Tang, W. H. W., Wang, A. Y.-M., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001088 · Cited by 63
Anderegg, M. D., Gums, T. H., Uribe, L., MacLaughlin, E. J., Hoehns, J. D., Bazaldua, O. V., Ives, T. J., Hahn, D. L., Coffey, C. S., & Carter, B. L. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2083 · Cited by 62
Ledwidge, M. T., O’Connell, E., Gallagher, J., Tilson, L., James, S., Voon, V., Bermingham, M., Tallon, E., Watson, C. J., O’Hanlon, R., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.286 · Cited by 61
Predictors of Sudden Cardiac Death
Shastri, S., Tangri, N., Tighiouart, H., Beck, G. J., Vlagopoulos, P. T., Ornt, D. B., Eknoyan, G., Kusek, J. W., Herzog, C. A., Cheung, A. K., et al. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06320611 · Cited by 60
Al‐Wahsh, H., Tangri, N., Quinn, R., Liu, P., Ferguson, T. W., Fiocco, M. F., Lam, N. N., Tonelli, M. A., & Ravani, P. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.9225 · Cited by 54
Fliotsos, M. J., Zhao, D., Rao, V. N., Ndumele, C. E., Güallar, E., Burke, G. L., Vaidya, D., Delaney, J. A., & Michos, E. D. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009599 · Cited by 52
Self-citationKatz, I. J., Pirabhahar, S., Williamson, P., Raghunath, V., Brennan, F. P., O’Sullivan, A., Youssef, G. S., Lane, C., Jacobson, G., Feldman, P. R., et al. (2017) · Nephrology · doi:10.1111/nep.13070 · Cited by 48
Thomas, M. B., MAGWIRE, M. L., GOSCH, K. L., Sammour, Y. M., Mehta, R., O’Keefe, J. H., Nassif, M. E., & Kosiborod, M. (2021) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.007682 · Cited by 47
Self-citationSakai, N., & Wada, T. (2014) · Kidney International · doi:10.1038/ki.2014.322 · Cited by 46
Reclassification of Pre-Heart Failure Stages Using Cardiac Biomarkers
Jia, X., Rifai, M. A., Ndumele, C. E., Virani, S. S., de Lemos, J. A., Lee, E., Shah, A. M., Echouffo-Tcheugui, J. B., Bozkurt, B., Hoogeveen, R. C., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2022.12.005 · Cited by 45
Self-citationCommodore-Mensah, Y. Y., Lazo, M., Tang, O., Echouffo-Tcheugui, J. B., Ndumele, C. E., Nambi, V., Wang, D., Ballantyne, C. M., & Selvin, E. (2021) · Diabetes Care · doi:10.2337/dc20-2227 · Cited by 43
Self-citationCompeting risks need to be considered in survival analysis models for cardiovascular outcomes
Huebner, M., Wolkewitz, M., Enriquez-Sarano, M. L., & Schumacher, M. C. (2017) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2016.12.039 · Cited by 42
Statins and All‐Cause Mortality in Patients Undergoing Hemodialysis
Jung, J., Bae, G. H., Kang, M., Kim, S. W., & Lee, D. H. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014840 · Cited by 42
Streja, E., Gosmanova, E. O., Molnar, M. Z., Soohoo, M., Moradi, H., Potukuchi, P. K., Kalantar‐Zadeh, K., & Kovesdy, C. P. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.2311 · Cited by 41
Cooper, H. L. F., Wells, S., & Mehta, S. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyab116 · Cited by 40
The Fibrates Story — A Tepid End to a PROMINENT Drug
Virani, S. S. (2022) · New England Journal of Medicine · doi:10.1056/nejme2213208 · Cited by 40
Self-citationNutrition Disparities and Cardiovascular Health
Mensah, G. A., Brown, A. G. M., & PRATT, C. A. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0833-3 · Cited by 39
Zhang, H., Huang, T., Shen, W., Xu, X., Yang, P., Zhu, D., Fang, H., Wan, H., Wu, T., Wu, Y., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12974 · Cited by 39
Nielsen, E. E., Feinberg, J. B., Bu, F.-L., Olsen, M. H., Raymond, I. E., Steensgaard-Hansen, F., & Jakobsen, J. C. (2020) · Open Heart · doi:10.1136/openhrt-2020-001294 · Cited by 39
Feng, Y., Yin, Y., Deng, R., & Li, H. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13243 · Cited by 36
Gallagher, C., Corl, A., & Dietz, W. H. (2021) · Obesity · doi:10.1002/oby.23154 · Cited by 32
Baker-Smith, C. M., Yang, W. C., McDuffie, M. J., Nescott, E., Wolf, B. J., Wu, C. H., Zhang, Z., & Akins, R. E. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.3012 · Cited by 32
Self-citationAtherosclerotic renal artery stenosis: current status and future directions
Zalunardo, N., & Tuttle, K. R. (2004) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200411000-00006 · Cited by 27
Self-citationFriedman, A. N., Schauer, P. R., Beddhu, S., Kramer, H., le Roux, C. W., Purnell, J. Q., Sunwold, D., Tuttle, K. R., Jastreboff, A. M., & Kaplan, L. M. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.06.007 · Cited by 27
Self-citationPark, D. Y., An, S., Murthi, M., Kattoor, A. J., Kaur, A., Ravi, V., Huang, H. D., & Vij, A. (2022) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-022-01168-2 · Cited by 24
Screening for Prediabetes and Diabetes: Clinical Performance and Implications for Health Equity
O’Brien, M. J., Zhang, Y., Bailey, S. C., Khan, S. S., Ackermann, R. T., Ali, M. K., Benoit, S. R., Imperatore, G., Holliday, C. S., & Bullard, K. M. (2023) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2023.01.007 · Cited by 23
Self-citationFakhry, M., Sidhu, M. S., Bangalore, S., et al. (2020) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2020.02.99 · Cited by 21
Research works printed but not linked: 1
- Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013;3:259–305.
Cited by
Sorted by citations
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001184 · Cited by 2,208
Self-citationDevelopment and validation of the American Heart Association’s PREVENT equations
Khan, S. S., Matsushita, K., Sang, Y., Ballew, S. H., Grams, M. E., Surapaneni, A., Blaha, M. J., Carson, A. P., Chang, A. R., Ciemins, E., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067626 · Cited by 1,234
Self-citationKhan, S. S., Coresh, J., Pencina, M. J., Ndumele, C. E., Rangaswami, J., Chow, S. L., Palaniappan, L. P., Sperling, L. S., Virani, S. S., Ho, J. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001191 · Cited by 797
Self-citationBadve, S. V., Bilal, A., Lee, M. M. Y., Sattar, N., Gerstein, H. C., Ruff, C. T., McMurray, J. J. V., Rossing, P., Bakris, G., Mahaffey, K. W., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00271-7 · Cited by 359
Self-citationJones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.05.007 · Cited by 280
Self-citation
Metadata
- Authors
- Ndumele, C. E., Neeland, I. J., Tuttle, K. R., Chow, S. L., Mathew, R. O., Khan, S. S., Coresh, J., Baker-Smith, C. M., Carnethon, M. R., Després, J.-P., Ho, J. E., Joseph, J. J., Kernan, W. N., Khera, A., Kosiborod, M. N., Lekavich, C. L., Lewis, E. F., Lo, K. B., Ozkan, B., Palaniappan, L. P., Patel, S. S., Pencina, M. J., Powell-Wiley, T. M., Sperling, L. S., Virani, S. S., Wright, J. T., Rajgopal Singh, R., Elkind, M. S. V., Rangaswami, J., & on behalf of the American Heart Association
- ORCID
- Ndumele, Chiadi E.
- Neeland, Ian J.
- Tuttle, Katherine R.
- Chow, Sheryl L.
- Mathew, Roy O.
- Khan, Sadiya S.
- Coresh, Josef
- Baker-Smith, Carissa M.
- Carnethon, Mercedes R.
- Després, Jean-Pierre
- Ho, Jennifer E.
- Joseph, Joshua J.
- Kernan, Walter N.
- Khera, Amit
- Kosiborod, Mikhail N.
- Lekavich, Carolyn L.
- Lewis, Eldrin F.
- Lo, Kevin B.
- Palaniappan, Latha P.
- Patel, Sonali S.
- Pencina, Michael J.
- Sperling, Laurence S.
- Virani, Salim S.
- Wright, Jackson T.
- Elkind, Mitchell S.V.
- Rangaswami, Janani
- Venue
- Circulation
- Published
- 2023-11-14
- Volume
- 148
- Issue
- 20
- Pages
- 1636-1664
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W4387435427
- Semantic Scholar
- 6defeae42f8fd0ab65e2d773c4ac2548dcdcbb45
- Cited by
- 1,405
- References
- 208
- Citations by year
- 2026: 694 · 2025: 569 · 2024: 134 · 2023: 8
- FWCI
- 50.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- eCommons - AKU (Aga Khan University) (submittedVersion)
- Funders
- American Heart Association
- Public Health Agency of Canada
- National Heart, Lung, and Blood Institute (R01HL140224)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- cardiovascular-kidney-metabolic syndrome, chronic kidney disease, cardiovascular disease, obesity, diabetes mellitus, metabolic risk factors, cardiovascular risk, renal outcomes, prevention, screening, lifestyle modification, weight loss, cardioprotective therapy, social determinants of health, competing risks, multidisciplinary care
- MeSH terms
- American Heart Association, Cardiovascular Diseases, Humans, Kidney, Risk Factors, United States, Metabolic Syndrome, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
